Trial Profile
An Open-Label Extension Study of Patients With Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Alglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genzyme Europe; Sanofi Genzyme
- 06 May 2017 New trial record
- 28 Apr 2017 Results assessing long-term efficacy of alglucosidase alfa in late-onset pompe disease patients from LOTS study, its open-label extension and Pompe Registry, presented at the 69th Annual Meeting of the American Academy of Neurology
- 25 Nov 2008 Status changed from active, no longer recruiting to completed.